Table 2 Clinical presentation between ESBL-positive EcBSI and ESBL-negative EcBSI
ESBL(−) | ESBL(+) | P-value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Integron(−) | Integron(+) | Integron(−) | Integron(+) | |||||||||||
Total | N | % | N | % | P-value | Total | N | % | N | % | P-value | |||
Sex | Male | 29 | 9 | 31.0 | 20 | 69.0 | 0.851 | 8 | 2 | 25.0 | 6 | 75.0 | 1.000 | 1.000 |
Female | 21 | 6 | 28.6 | 15 | 71.4 | 12 | 4 | 33.3 | 8 | 66.7 | 1.000 | |||
Previous antibiotics at the empirical stage before | No | 24 | 1 | 5.0 | 23 | 95.0 | 1.000 | 17 | 7 | 41.2 | 10 | 58.8 | 1.000 | 0.023 |
E. cloacae infection | Yes | 26 | 16 | 61.0 | 10 | 39.0 | 3 | 1 | 33.3 | 2 | 66.7 | |||
Prognosis | Survival | 38 | 18 | 47.4 | 20 | 52.6 | 0.874 | 8 | 2 | 25.0 | 6 | 75.0 | 1.000 | 0.435 |
Expired | 12 | 6 | 50.0 | 6 | 50.0 | 12 | 2 | 16.7 | 10 | 83.3 | 0.193 | |||
Type of infection | Primary | 1 | 0 | 0.0 | 1 | 100.0 | 1.000 | 5 | 2 | 0.0 | 3 | 100.0 | 1.000 | |
Secondary | 49 | 9 | 18.4 | 40 | 81.6 | 15 | 4 | 21.1 | 11 | 78.9 | 1.000 | |||
Secondary infection (multiple) | Total | 49 | 19 | 30 | 15 | 5 | 10 | |||||||
Respiratory tract | 30 | 10 | 33.3 | 20 | 66.7 | 0.326 | 3 | 1 | 33.3 | 2 | 66.7 | 0.370 | 1.000 | |
Urinary tract | 12 | 2 | 16.7 | 10 | 83.3 | 0.095 | 6 | 1 | 5 | 0.023 | 1.000 | |||
Catheter-related | 2 | 0 | 0.0 | 2 | 100.0 | 0.515 | 0 | 0 | 0.0 | 0 | 100.0 | 1.000 | ||
Intra-abdominal infection | 9 | 2 | 22.2 | 7 | 77.8 | 0.451 | 6 | 0 | 0.0 | 6 | 100.0 | 0.474 | 1.000 | |
CNS infection | 3 | 1 | 33.3 | 2 | 66.7 | 1.000 | 0 | 0 | 0.0 | 0 | 0.0 | |||
Others | 3 | 1 | 33.3 | 2 | 66.7 | 1.000 | 0 | 0 | 0.0 | 0 | 00 | 0.474 | 1.000 | |